Ribomic, Inc. (JP:4591)
:4591
Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥72.00 - ¥141.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥4.13B
Enterprise Value¥1.77B
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,072,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero total debt and a net-cash posture materially reduce refinancing risk and interest burden, giving management time to advance R&D and pursue partnerships. This durable liquidity buffer supports operations and strategic optionality over the next several quarters.
Proprietary Technology PlatformA focused aptamer platform creates a sustainable competitive moat in niche therapeutic areas (ophthalmology, rare diseases). Proprietary IP supports licensing, collaborations, and potential royalty streams, underpinning recurring revenue potential beyond single assets.
Rebound In Revenue GrowthA sharp revenue rebound from a low base indicates improving commercial traction of licensing and collaboration activities. Durable, growing partnership revenues can help de-risk development cash needs and signal broader acceptance of the platform by pharma partners.
Bears Say
Persistent Cash BurnConsistent negative OCF and FCF mean the company must rely on existing cash, equity issuance, or partner milestones to fund R&D. This structural cash burn shortens runway and raises the probability of dilutive financings within a multi-quarter horizon.
Deep UnprofitabilitySustained, large operating and net losses indicate current margins are unsustainable relative to scale. Without clear near-term path to break-even, profitability depends on successful commercialization or non-dilutive partner funding, elevating execution risk.
Erosion Of Equity BaseDeclining shareholders' equity reduces the firm’s capital buffer and strategic flexibility. Even with no debt, continued erosion increases reliance on external funding and could constrain deal-making or R&D expansion over the medium term.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥72.00 and its highest was ¥141.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥4.13B.
When is Ribomic, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ribomic, Inc.’s earnings last quarter?
Currently, no data Available
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 55,072,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Linical Co., Ltd.
―
CanBas Co., Ltd.
―
Takara Bio Inc.
―